Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
CEO: Albert A. Manzone. Company website
Perrigo Company plc (PRGO) trades at $13.56, up 0.59% on the day, as of Sep 20, 2026 14:59 UTC.
Perrigo Company plc has a market capitalisation of $1.88B, calculated from the live PRGO share price and shares outstanding.
PRGO has no meaningful price-to-earnings ratio: Perrigo Company plc lost $12.52 per share over the last twelve months, and a P/E is only defined on positive earnings.
Perrigo Company plc generated revenue of $4.14B over the trailing twelve months, which puts the stock at 0.45 times sales.
Yes. Perrigo Company plc pays a dividend yielding 7.84% on the current share price.
PRGO has traded between $9.23 and $22.65 over the past 52 weeks, and the last price is 40.1% below that high.
No. Perrigo Company plc is loss-making, with a net margin of -41.85% over the trailing twelve months.
Wall Street analysts rate PRGO Hold, with an average price target of $36.20, 167.0% above the current price.
Perrigo Company plc is classified under the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is domiciled in IE.
Albert A. Manzone is the chief executive of Perrigo Company plc, which employs 8,100 people.
QFI Terminal shows PRGO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PRGO in Terminal See plans